Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.0350-0.0050 (-12.50%)
At close: 03:23PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0400
Open0.0400
Bid0.0300 x N/A
Ask0.0400 x N/A
Day's Range0.0350 - 0.0400
52 Week Range0.0350 - 0.2900
Volume436,600
Avg. Volume312,923
Market Cap14.818M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.1100
Earnings DateJul 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TBP.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the "Financing") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean ("ABO"), and has closed the first tranche of the Financing on such revised terms, the whole pursuant to the term

    • CNW Group

      IIROC Trade Resumption - TBP

      Trading resumes in:

    • PR Newswire

      Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC ("Cellvera"), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

    Advertisement
    Advertisement